VYGR
Price
$5.00
Change
-$0.15 (-2.91%)
Updated
Oct 10 closing price
Capitalization
277.34M
37 days until earnings call
XENE
Price
$39.64
Change
-$1.64 (-3.97%)
Updated
Oct 10 closing price
Capitalization
3.06B
24 days until earnings call
Interact to see
Advertisement

VYGR vs XENE

Header iconVYGR vs XENE Comparison
Open Charts VYGR vs XENEBanner chart's image
Voyager Therapeutics
Price$5.00
Change-$0.15 (-2.91%)
Volume$894.4K
Capitalization277.34M
Xenon Pharmaceuticals
Price$39.64
Change-$1.64 (-3.97%)
Volume$940.78K
Capitalization3.06B
VYGR vs XENE Comparison Chart in %
VYGR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
VYGR vs. XENE commentary
Oct 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VYGR is a Hold and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 12, 2025
Stock price -- (VYGR: $5.00 vs. XENE: $39.64)
Brand notoriety: VYGR and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: VYGR: 116% vs. XENE: 119%
Market capitalization -- VYGR: $277.34M vs. XENE: $3.06B
VYGR [@Biotechnology] is valued at $277.34M. XENE’s [@Biotechnology] market capitalization is $3.06B. The market cap for tickers in the [@Biotechnology] industry ranges from $104.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

VYGR’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • VYGR’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, both VYGR and XENE are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

VYGR’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • VYGR’s TA Score: 5 bullish, 4 bearish.
  • XENE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XENE is a better buy in the short-term than VYGR.

Price Growth

VYGR (@Biotechnology) experienced а +5.93% price change this week, while XENE (@Biotechnology) price change was +0.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.93%. For the same industry, the average monthly price growth was +14.64%, and the average quarterly price growth was +82.08%.

Reported Earning Dates

VYGR is expected to report earnings on Nov 18, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+3.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($3.06B) has a higher market cap than VYGR($277M). XENE YTD gains are higher at: 1.122 vs. VYGR (-11.817). VYGR has higher annual earnings (EBITDA): -119.18M vs. XENE (-315.5M). XENE has more cash in the bank: 488M vs. VYGR (43.9M). XENE has less debt than VYGR: XENE (8.72M) vs VYGR (40.2M). VYGR has higher revenues than XENE: VYGR (42.6M) vs XENE (7.5M).
VYGRXENEVYGR / XENE
Capitalization277M3.06B9%
EBITDA-119.18M-315.5M38%
Gain YTD-11.8171.122-1,053%
P/E Ratio6.00N/A-
Revenue42.6M7.5M568%
Total Cash43.9M488M9%
Total Debt40.2M8.72M461%
FUNDAMENTALS RATINGS
VYGR vs XENE: Fundamental Ratings
VYGR
XENE
OUTLOOK RATING
1..100
3020
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
10035
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
4146
P/E GROWTH RATING
1..100
85
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VYGR's Valuation (45) in the Biotechnology industry is in the same range as XENE (72). This means that VYGR’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (35) in the Biotechnology industry is somewhat better than the same rating for VYGR (100). This means that XENE’s stock grew somewhat faster than VYGR’s over the last 12 months.

XENE's SMR Rating (97) in the Biotechnology industry is in the same range as VYGR (97). This means that XENE’s stock grew similarly to VYGR’s over the last 12 months.

VYGR's Price Growth Rating (41) in the Biotechnology industry is in the same range as XENE (46). This means that VYGR’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (5) in the Biotechnology industry is in the same range as VYGR (8). This means that XENE’s stock grew similarly to VYGR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
VYGRXENE
RSI
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
78%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 4 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 6 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
75%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
VYGR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGIBX41.97N/A
N/A
MFS International Intrinsic Value B
GEMIX30.01N/A
N/A
Goldman Sachs Emerging Markets Eq Instl
DHPYX18.22N/A
N/A
Diamond Hill Mid Cap Y
MSGRX13.30N/A
N/A
Meridian Small Cap Growth Institutional
BIRKX23.75N/A
N/A
BlackRock Sust Awr Advtg Lg Cp Cr K

VYGR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VYGR has been loosely correlated with RGNX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if VYGR jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VYGR
1D Price
Change %
VYGR100%
-2.91%
RGNX - VYGR
53%
Loosely correlated
-10.27%
KYMR - VYGR
50%
Loosely correlated
+0.33%
IMNM - VYGR
47%
Loosely correlated
-2.59%
IMTX - VYGR
47%
Loosely correlated
-4.95%
XNCR - VYGR
47%
Loosely correlated
-0.23%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with NUVL. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-3.97%
NUVL - XENE
62%
Loosely correlated
+0.11%
IDYA - XENE
57%
Loosely correlated
-2.05%
NRIX - XENE
53%
Loosely correlated
-10.13%
CRNX - XENE
51%
Loosely correlated
-1.81%
XNCR - XENE
50%
Loosely correlated
-0.23%
More